Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck.
MacDonald GC, Rasamoelisolo M, Entwistle J, Cizeau J, Bosc D, Cuthbert W, Kowalski M, Spearman M, Glover N. MacDonald GC, et al. Among authors: rasamoelisolo m. Drug Des Devel Ther. 2009 Feb 6;2:105-14. doi: 10.2147/dddt.s3442. Drug Des Devel Ther. 2009. PMID: 19920898 Free PMC article.
A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck.
MacDonald GC, Rasamoelisolo M, Entwistle J, Cuthbert W, Kowalski M, Spearman MA, Glover N. MacDonald GC, et al. Among authors: rasamoelisolo m. Med Oncol. 2009;26(3):257-64. doi: 10.1007/s12032-008-9111-x. Epub 2008 Oct 28. Med Oncol. 2009. PMID: 19016010 Clinical Trial.
A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe.
Cherniakov I, Cohen-Barak O, Tiver R, Gillespie M, Kessler Y, Gutierrez M, Rasamoelisolo M, Li S, Shen H, Hallak H, Loupe PS, Smith M, Rabinovich-Guilatt L, Spiegelstein O. Cherniakov I, et al. Among authors: rasamoelisolo m. Clin Pharmacol Drug Dev. 2021 Sep;10(9):1018-1027. doi: 10.1002/cpdd.902. Epub 2021 Jan 7. Clin Pharmacol Drug Dev. 2021. PMID: 33411992 Free PMC article. Clinical Trial.
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects.
Cohen-Barak O, Weiss S, Rasamoelisolo M, Faulhaber N, Yeung PP, Loupe PS, Yoon E, Gandhi MD, Spiegelstein O, Aycardi E. Cohen-Barak O, et al. Among authors: rasamoelisolo m. Cephalalgia. 2018 Nov;38(13):1960-1971. doi: 10.1177/0333102418771376. Epub 2018 Apr 18. Cephalalgia. 2018. PMID: 29667896 Clinical Trial.
Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach.
Cohen-Barak O, Radivojevic A, Jones A, Fiedler-Kelly J, Gillespie M, Brennan M, Gutman D, Rasamoelisolo M, Hallak H, Loupe P, Kessler Y, Ning X, Levi M, Ahn AH, Rabinovich-Guilatt L. Cohen-Barak O, et al. Among authors: rasamoelisolo m. Cephalalgia. 2021 Sep;41(10):1065-1074. doi: 10.1177/03331024211007789. Epub 2021 May 17. Cephalalgia. 2021. PMID: 34000848 Clinical Trial.
Immunogenicity of biologic therapies for migraine: a review of current evidence.
Cohen JM, Ning X, Kessler Y, Rasamoelisolo M, Campos VR, Seminerio MJ, Krasenbaum LJ, Shen H, Stratton J. Cohen JM, et al. Among authors: rasamoelisolo m. J Headache Pain. 2021 Jan 7;22(1):3. doi: 10.1186/s10194-020-01211-5. J Headache Pain. 2021. PMID: 33413094 Free PMC article. Review.
18 results